Combination gemcitabine, platinum, and bevacizumab for the treatment of recurrent ovarian cancer

Gynecologic Oncology

Volumn 111, Issue 3, 2008, Pages 461-466

  Richardson, Debra L ^a   Backes, Floor J ^a   Seamon, Leigh G ^a   Zanagnolo, Vanna ^a   O'Malley, David M ^a   Cohn, David E ^a   Fowler, Jeffrey M ^a   Copeland, Larry J ^a  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Bevacizumab; Bowel perforation; Gemcitabine; Platinum; Recurrent epithelial ovarian cancer

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; GEMCITABINE; PLATINUM;

ADULT; AGED; ALLERGY; ANEMIA; ARTICLE; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONSTIPATION; CRANIAL NEUROPATHY; CREATININE BLOOD LEVEL; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG EFFICACY; DYSPNEA; FATIGUE; FEMALE; FOLLOW UP; HEADACHE; HUMAN; HYPERTENSION; LEUKOPENIA; LIVER FUNCTION TEST; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVARY CANCER; PAIN; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RASH; SENSORY NEUROPATHY; SIDE EFFECT; THROMBOCYTOPENIA; THROMBOEMBOLISM; VAGINA DISEASE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CA-125 ANTIGEN; CARBOPLATIN; CISPLATIN; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 56449105264     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2008.08.011     Document Type: Article

References (38)

1. Ries LAG MD, Krapcho M, Mariotto A, et al. SEER Cancer Statistics Review, 1975-2004, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2004/, based on November 2006 SEER data submission, posted to the SEER web site, 2007.
2. American Cancer Society. Facts and Figures. 2008.
3. Bhoola S., and Hoskins W.J. Diagnosis and management of epithelial ovarian cancer. Obstet. Gynecol. 107 (2006) 1399-1410
4. Peters G.J., Bergman A.M., Ruiz van Haperen V.W., Veerman G., Kuiper C.M., and Braakhuis B.J. Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin. Oncol. 22 (1995) 72-79
5. Rose P.G., Mossbruger K., Fusco N., Smrekar M., Eaton S., and Rodriguez M. Gemcitabine reverses cisplatin resistance: demonstration of activity in platinum- and multidrug-resistant ovarian and peritoneal carcinoma. Gynecol. Oncol. 88 (2003) 17-21
6. Pfisterer J., Plante M., Vergote I., et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J. Clin. Oncol. 24 (2006) 4699-4707
7. Bozas G., Bamias A., Koutsoukou V., et al. Biweekly gemcitabine and cisplatin in platinum-resistant/refractory, paclitaxel-pretreated, ovarian and peritoneal carcinoma. Gynecol. Oncol. 104 (2007) 580-585
8. Brewer C.A., Blessing J.A., Nagourney R.A., Morgan M., and Hanjani P. Cisplatin plus gemcitabine in platinum-refractory ovarian or primary peritoneal cancer: a phase II study of the Gynecologic Oncology Group. Gynecol. Oncol. 103 (2006) 446-450
9. Tewari D., Monk B.J., Hunter M., Falkner C.A., and Burger R.A. Gemcitabine and cisplatin chemotherapy is an active combination in the treatment of platinum-resistant ovarian and peritoneal carcinoma. Invest New Drugs 22 (2004) 475-480
10. Folkman J., Watson K., Ingber D., and Hanahan D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 339 (1989) 58-61
11. Ranieri G., Patruno R., Ruggieri E., Montemurro S., Valerio P., and Ribatti D. Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic. Curr. Med. Chem. 13 (2006) 1845-1857
12. Abulafia O., Triest W.E., and Sherer D.M. Angiogenesis in primary and metastatic epithelial ovarian carcinoma. Am. J. Obstet. Gynecol. 177 (1997) 541-547
13. Alvarez A.A., Krigman H.R., Whitaker R.S., Dodge R.K., and Rodriguez G.C. The prognostic significance of angiogenesis in epithelial ovarian carcinoma. Clin. Cancer Res. 5 (1999) 587-591
14. Goodheart M.J., Vasef M.A., Sood A.K., Davis C.S., and Buller R.E. Ovarian cancer p53 mutation is associated with tumor microvessel density. Gynecol. Oncol. 86 (2002) 85-90
15. Hollingsworth H.C., Kohn E.C., Steinberg S.M., Rothenberg M.L., and Merino M.J. Tumor angiogenesis in advanced stage ovarian carcinoma. Am. J. Pathol. 147 (1995) 33-41
16. Raspollini M.R., Amunni G., Villanucci A., Baroni G., Boddi V., and Taddei G.L. Prognostic significance of microvessel density and vascular endothelial growth factor expression in advanced ovarian serous carcinoma. Int. J. Gynecol. Cancer 14 (2004) 815-823
17. Kim K.J., Li B., Winer J., et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362 (1993) 841-844
18. Warren R.S., Yuan H., Matli M.R., Gillett N.A., and Ferrara N. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J. Clin. Invest. 95 (1995) 1789-1797
19. Rubenstein J.L., Kim J., Ozawa T., et al. Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia 2 (2000) 306-314
20. Presta L.G., Chen H., O'Connor S.J., et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 57 (1997) 4593-4599
21. Yang J.C., Haworth L., Sherry R.M., et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med. 349 (2003) 427-434
22. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350 (2004) 2335-2342
23. Manegold C.v.P.J., Zatloukal P., Ramlau R., et al. Randomised, double-blind multicentre phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapy-naïve patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): BO17704. J Clin Oncol 25 18S (2007) LBA7514
24. Burger R.A., Sill M.W., Monk B.J., Greer B.E., and Sorosky J.I. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J. Clin. Oncol. 25 (2007) 5165-5171
25. Cannistra S.A., Matulonis U.A., Penson R.T., et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J. Clin. Onco. 25 (2007) 5180-5186
26. Monk B.J., Han E., Josephs-Cowan C.A., Pugmire G., and Burger R.A. Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancer. Gynecol. Oncol. 102 (2006) 140-144
27. Garcia A.A., Hirte H., Fleming G., et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J. Clin. Oncol. 26 (2008) 76-82
28. Wright J.D., Hagemann A., Rader J.S., et al. Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: a retrospective analysis. Cancer 107 (2006) 83-89
29. Cohn D.E., Valmadre S., Resnick K.E., Eaton L.A., Copeland L.J., and Fowler J.M. Bevacizumab and weekly taxane chemotherapy demonstrates activity in refractory ovarian cancer. Gynecol. Oncol. 102 (2006) 134-139
30. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst. 92 (2000) 205-216
31. Guppy A.E., and Rustin G.J. CA125 response: can it replace the traditional response criteria in ovarian cancer?. Oncologist 7 (2002) 437-443
32. Friberg G., Oza A.M., Morgan R.J., et al. Bevacizumab plus erlotinib for patients with recurrent ovarian and fallopian tube cancer; preliminary results of a multi-center phase II trial. J Clin Oncol 24 18S (2006) 5018
33. Simpkins F., Belinson J.L., and Rose P.G. Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening. Gynecol. Oncol. 107 (2007) 118-123
34. Wright J.D., Secord A.A., Numnum T.M., et al. A multi-institutional evaluation of factors predictive of toxicity and efficacy of bevacizumab for recurrent ovarian cancer. Int. J. Gynecol. Cancer 18 (2007) 400-406
35. Kose M.F., Sufliarsky J., Beslija S., et al. A phase II study of gemcitabine plus carboplatin in platinum-sensitive, recurrent ovarian carcinoma. Gynecol. Oncol. 96 (2005) 374-380
36. Nagourney R.A., Brewer C.A., Radecki S., et al. Phase II trial of gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed ovarian cancer patients. Gynecol. Oncol. 88 (2003) 35-39
37. Germano D., Rosati G., and Manzione L. Gemcitabine combined with oxaliplatin (GEMOX) as salvage treatment in elderly patients with advanced ovarian cancer refractory or resistant to platinum: a single institution experience. J. Chemother. 19 (2007) 577-581
38. Arca R., Lerzo M., Mandachain M., et al. Gemcitabine (GEM)+ oxaliplatin (OX) in patients (pts) with stage III/IV ovarian cancer following 3 cycles of carboplatin (CB)+ paclitaxel (PAC): Preliminary report of a phase II study. J Clin Oncol 22 14S (2004) 5111